The MarketReader Minute
💊 Ascendis Surges on Achondroplasia Breakthrough and Nuvalent Advances Lung Cancer Trials | Biotech Sector Insights
Ascendis Pharma A/S (ASND) experienced a notable stock increase following positive results from the ApproaCH Trial, which demonstrated superior growth velocity in children with achondroplasia.